Adverse Events and Predictive Probability of Peripheral Vasopressor Administration in Pediatric Shock: Integrating Frequentist and Hierarchical Bayesian Meta-Analyses

Mario Martinez-Solarte¹Jaime Fernández-Sarmiento^2,3*Lucia Guzman³Daniel Fernández-Sarta⁴Lina Gutierrez-Montenegro³Ana Maria Sarmiento²Hernando Mulett^2,4Maria Carolina Fernández-Palacio³Juan David Suarez³Jonathan Mejia²Raul Rafael Copana Olmos⁵Nils Casson⁶Diana Bravo⁷Anhi Martinez²Daniela Guayambuco³Mariana Rios³Tejas Girishkumar Mehta⁸Javier Urbano⁹

• ¹Universidad del Rosario, Bogotá, Colombia
• ²Cardioinfantil Foundation, Bogotá, Colombia
• ³Universidad de La Sabana, Chia, Colombia
• ⁴Fundacion Cardioinfantil Instituto de Cardiologia, Bogotá, Colombia
• ⁵Universidad Mayor de San Simon, Cochabamba, Bolivia
• ⁶Hospital Universitaria Municipal San Juan de Dios, Santa Cruz de la Sierra, Bolivia
• ⁷Fundacion HOMI Hospital de la Misericordia, Bogotá, Colombia
• ⁸Hamad Medical Corporation Department of Medical Education, Doha, Qatar
• ⁹Hospital General Universitario Gregorio Maranon, Madrid, Spain

Background: Pediatric shock demands early vasoactive therapy to restore perfusion. When central access is delayed—particularly in resource-limited settings—peripheral vasopressors provide a feasible alternative. This systematic review and hierarchical Bayesian meta-analysis synthesized current evidence on peripheral vasopressor use in children, estimating incidence, characteristics, and probabilistic risk of local complications to inform safe clinical practice. Methods: We systematically searched PubMed/MEDLINE, EMBASE, LILACS, Google Scholar, and the Cochrane Library (January 1990–March 2025) using MeSH and free-text terms for vasoactive agents, peripheral intravenous access, pediatric populations, and adverse events. Studies including children aged 1 month–18 years who received peripheral vasopressors and reported local complications were eligible. Two reviewers independently extracted data and assessed study quality using the Joanna Briggs Institute (JBI) checklist. The primary outcome was the pooled proportion of local adverse events. Frequentist and hierarchical Bayesian logistic models estimated pooled rates, 95% confidence or credible intervals, and predictive uncertainty. Weakly informative priors (half-Cauchy for random effects, normal[0,1] for log-odds) were applied, and posterior estimates derived via Markov Chain Monte Carlo (four chains, 2,000 iterations, R̂ < 1.01). Results: Eleven studies comprising 1,575 pediatric patients were included. The pooled incidence of local adverse events was 1.97% (95% CI, 1.41–2.82) with no severe complications such as necrosis, ischemia, or need for surgery. The Bayesian model yielded a consistent pooled rate of 1.8% (CrI95%, 1.0–2.8), with a 68% probability of being below 2% and 99% below 3%. Predictive intervals suggested new studies of 100–300 patients would show rates between 0–5%, confirming reproducibility. Subgroup analyses revealed no meaningful differences by setting or catecholamine type. Most events were mild extravasations after a median infusion of 4.1 hours (IQR, 2.9–7.1). Conclusions: Peripheral vasopressor administration in pediatric shock is associated with a very low incidence of local adverse events. The Bayesian hierarchical model confirmed these findings with high probabilistic confidence, supporting peripheral administration as a safe and rapid approach for early hemodynamic stabilization. Peripheral vasopressors may be used for short durations (typically <4 hours, according to the included studies) while central access is being established, thereby minimizing delays in critical resuscitation.